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 Ultrafiltration was used to collect lamellar interstitial fluid for pharmacokinetic 19 
analyses 20 
 Intraosseous infusion of the distal phalanx (IOIDP) with marimastat results in similar 21 
lamellar marimastst concentrations to systemic intravenous constant rate infusion.  22 
 Further refinement of the IOIDP technique is necessary if it is to be useful for local 23 
lamellar drug delivery. 24 
Abstract 25 
 26 
No validated laminitis drug therapy exists, yet pharmaceutical agents with potential 27 
for laminitis prevention have been identified. Many of these are impractical for systemic 28 
administration but may be effective if administered locally. This study compared intraosseous 29 
infusion of the distal phalanx (IOIDP) with systemic intravenous constant rate infusion (CRI) 30 
to determine which was more effective for lamellar marimastat delivery. Ultrafiltration 31 
probes were placed in both forefeet of five horses to collect lamellar interstitial fluid as 32 
lamellar ultrafiltrate (LUF). Marimastat solution (3.5 mg/mL) containing lidocaine (20 33 
mg/mL) was infused by IOIDP at 0.15 mL/min for 12 h. After a 12 h wash-out, marimastat 34 
(3.5 mg/mL) and lidocaine were infused by constant rate infusion (CRI) at 0.15 mL/min for 35 
12 h. LUF, plasma and lamellar tissue marimastat concentrations were quantified using 36 
UPLC-MS. Zymography was used to establish the inhibitory concentrations of marimastat for 37 
equine lamellar matrix metalloproteinases (MMPs). Data were analysed non-parametrically. 38 
 39 
There was no difference between the steady-state marimastat concentration in 40 
lamellar ultrafiltrate (LUF[M]) during IOIDP (139[88-497] ng/mL) and CRI (136[93-157] 41 
ng/mL). During IOIDP, there was no difference between marimastat concentrations in the 42 
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treated foot (139[88-497] ng/mL), the untreated foot (91[63-154] ng/mL) and plasma 43 
(101[93-118] ng/mL). LUF[M] after IOIDP and CRI were >IC50 of lamellar MMP-2 and 9, but 44 
below the concentration considered necessary for in vivo laminitis prevention. Lamellar drug 45 
delivery during IOIDP was inconsistent and did not achieve higher lamellar marimastat 46 
concentrations than CRI. Modification or refinement of the IOIDP technique is necessary if it 47 
is to be consistently effective.  48 
 49 
Keywords: Horse; MMP-inhibitor; Pharmacokinetics; Laminitis; Ultrafiltration. 50 
Introduction 51 
Laminitis is a crippling disease of the equine foot. There are no experimentally 52 
validated pharmacological means of treating or preventing laminitis. Activation of matrix 53 
metalloproteinases (MMPs) and ADAMTS (a disintegrin and metalloproteinase with 54 
thrombospondin motifs)-4 has been implicated in inflammatory laminitis pathophysiology 55 
(Pollitt et al., 1998; Visser, 2009; Wang et al., 2012).  The broad spectrum MMP inhibitors 56 
marimastat and batimastat prevent lamellar separation in vitro (Pollitt et al., 1998). They also 57 
inhibit ADAMTS-4 (Tortorella et al., 2009). Investigation of their in vivo efficacy is 58 
warranted, but has been prevented by their impracticality for systemic administration due to 59 
expense, systemic side effects (Levin et al., 2006), and rapid clearance after intravenous (IV) 60 
administration (M.A. Pass and C.C. Pollitt, unpublished data).  A regional lamellar delivery 61 
technique is required for experimental evaluation of their anti-laminitis potential. 62 
 63 
IOIDP has been investigated for short-term delivery of gentamicin to lamellar tissue 64 
(Nourian et al., 2010). Lamellar gentamicin concentrations were significantly higher than 65 
those in plasma, suggesting IOIDP had potential for regional lamellar delivery. However, 66 
administration of insulin by IOIDP over 48 h resulted in foot pain and no evidence of 67 
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effective local delivery (de Laat, 2011). Further investigation is warranted to determine if 68 
long-term IOIDP results in regional lamellar delivery and whether the technique is tolerated 69 
by the subject.  70 
 71 
In this study, a modified intraosseous (IO) infusion of the distal phalanx (IOIDP) 72 
technique was compared with systemic constant rate infusion (CRI) to determine which 73 
delivered marimastat more effectively to the lamellar region of the horse’s foot. Lamellar 74 
ultrafiltrate (LUF) obtained via lamellar ultrafiltration enabled sampling of lamellar 75 
interstitial fluid. The following hypotheses were tested: (1) IOIDP results in higher LUF 76 
marimastat concentrations (LUF[M]) than CRI, and (2) LUF[M] in the foot receiving IOIDP are 77 
higher than those in the contra-lateral limb and in plasma (P[M]). An additional objective was 78 
to further validate lamellar ultrafiltration for pharmacokinetic studies. Variations in LUF[M] 79 
and biochemical analyte (glucose, urea, sodium, potassium and chloride) concentrations over 80 
time, along with the difference between LUF[M] and lamellar tissue marimastat concentrations 81 
(T[M]), were examined. 82 
 83 
Materials and methods 84 
The project was approved by the University of Queensland Animal Ethics Committee 85 
(AEC) (approval numbers SVS/337/11 and SVS/418/12) that monitors compliance with the 86 
Animal Welfare Act (2001) and the Australian Code of Practice for the Care and Use of 87 
Animals for Scientific Purposes (current edition). 88 
 89 
Animals and monitoring 90 
Five Standardbred horses (four geldings, one mare; aged 6-11 years, 447-502 kg), 91 
with no lameness or gross foot abnormalities were enrolled in the study. During the 92 
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experiment the horses were housed in stalls with ad libitum access to hay and water, and 93 
monitored continuously. Heart rate, respiratory rate and pain behaviours were recorded at 0, 94 
1, 2, 3, 4, 5, 6, 9 and 12 h during both IOIDP and CRI.  95 
 96 
In vitro marimastat recovery 97 
Stock solutions of marimastat (BB-2516, Vernalis) at 0.1, 0.5, 1, 10 and 100 µg/mL 98 
were prepared in pooled plasma and 0.9% saline; 200 µL of each stock solution were stored 99 
for analysis. Custom-made 3-8 ultrafiltration probes (BASi) were placed into 5 mL of each 100 
stock solution. Ultrafiltrate was collected for 2 h at 37 ⁰C. Experiments were performed in 101 
triplicate and samples stored at -80 ⁰C prior to analysis by ultra-performance liquid 102 
chromatography with tandem mass spectroscopy (UPLC-MS).  Recovery was calculated 103 
according to the following equation:  104 
 105 
         
                              
                                 
   100 106 
 107 
Zymography 108 
To assess the potency and efficacy of marimastat on equine lamellar MMP-2 and 9, 109 
an in vitro gel zymography bioassay was used. Gelatin zymography was performed as 110 
previously described with minor variations (Pollitt et al., 1998; de Laat et al., 2011). Briefly, 111 
pooled lamellar tissue collected from horses 48 h after administration of 10 g/kg 112 
oligofructose (archived from a separate study) was homogenised (by pulverising the tissue to 113 
a powder in liquid nitrogen, and then re-suspending it in phosphate-buffered saline), 114 
centrifuged and the total protein concentration in the supernatant determined. Samples 115 
containing 10 µg protein were prepared and run on 7.5% acrylamide mini-gels containing 116 
0.25% gelatine. Lanes were separately incubated with marimastat at different concentrations 117 
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(range 1 – 1000 ng/mL plus control) in gelatine refolding buffer for 24 h. Gels were stained 118 
then analysed by band densitometry (Unscan-it Software, Silk Scientific).  Densitometry data 119 
were expressed as % of activity of control and experiments were repeated four times. 120 
 121 
In vivo study design and sample collection 122 
Twenty-four hours prior to IOIDP, ultrafiltration probes were placed in the lamellar 123 
region of each forelimb. IV catheters were placed in the left and right jugular veins (for blood 124 
collection and drug administration respectively). An IO cannula was placed in the distal 125 
phalanx of one forelimb on each horse (instrumented foot). Sterile marimastat solution (3.5 126 
mg/mL marimastat, 20 mg/mL lidocaine [Ilium Lidocaine, Troy Laboratories] and 1.5 IU/mL 127 
heparin sodium [Pfizer]) were infused through the IO cannula with a target infusion rate of 128 
0.25 mL/min.  129 
 130 
Jugular blood and LUF from the instrumented foot were collected prior to marimastat 131 
administration, then at 1, 2, 3, 4, 5, 6, 9 and 12 h of infusion. LUF was collected from the 132 
contralateral, uninstrumented foot at 0, 6, 9 and 12 h. The volume of marimastat solution 133 
infused was recorded. After 12 h the IOIDP cannula was perfused with heparin and lidocaine 134 
solution for 1 h to remove residual marimastat then sealed. The horses underwent a 12 h 135 
wash-out period (12  elimination half-life (59 ± 21 min) after systemic IV administration to 136 
horses (M.A. Pass and C.C. Pollitt, unpublished data) prior to CRI. 137 
 138 
Baseline LUF samples were collected 1 h prior to CRI. An identical marimastat 139 
solution was administered by CRI through the right jugular catheter using microinfusion 140 
pumps at the same rate as the mean IOIDP infusion rate in that horse with sample collection 141 
time-points as for IOIDP. At the end of the CRI horses were euthanased with pentobarbital 142 
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sodium (Lethabarb, 20 mg/kg IV). Lamellar tissue encompassing the ultrafiltration probe was 143 
collected for histological and pharmacokinetic analyses.  144 
 145 
Ultrafiltration probe placement 146 
Sterile, custom-made ultrafiltration probes (3-8 UF) were placed in the lamellar 147 
region of both forelimbs under regional anaesthesia as previously described, with the minor 148 
variation that the probes were placed 1-2 cm lateral to dorsal midline  (Underwood et al., 149 
2014) The ultrafiltration tubing was cut to a length of 30 cm from the probe prior to sample 150 
collection. The location of the probe was marked on the surface of the hoof wall to ensure the 151 
probe was not damaged during IOIDP needle placement. 152 
  153 
IOIDP needle placement 154 
After sedation with 0.03 mg/kg acepromazine (A.C.P. 10, Delvet) and bilateral 155 
perineural anaesthesia of the palmar digital nerves at the fetlock and metacarpal nerves at the 156 
distal aspect of the 2nd and 4th metacarpal bones using mepivacaine (Ilium Vetacaine), the 157 
dorsal hoof was rasped and aseptically prepared. A midline site 25 mm below the hairline and 158 
1-2 cm medial to the ultrafiltration probe was marked on the hoof wall. A 3.2 mm diameter 159 
hole was drilled perpendicular to the hoof wall. Drilling continued until the dorsal surface of 160 
the distal phalanx was contacted. The drill bit was adjusted so that further drilling extended 4 161 
mm into the distal phalanx. The hoof wall was then over-drilled with a 4.8 mm drill bit. 162 
 163 
A sterile 25 mm long nylon dummy needle with a bevelled tip was driven into the 164 
distal phalanx, flushed and withdrawn to remove any remaining debris. A sterile, custom 165 
made, IO needle (Fig. 1) formed from nylon tubing with an external diameter of 3.2 mm and 166 
a 1.6 mm hose barb elbow connector was primed with sterile heparinised saline, inserted into 167 
Page 7 of 25
8 
 
the distal phalanx and tapped into place until the elbow was flush with the hoof surface. A 168 
120 cm plastic extension tube (Pressure Tubing, Edwards) preloaded with sterile heparinised 169 
saline was connected to the needle and flushed. Hoof adhesive (Equilox) was applied to fix 170 
the tubing in place. Infusion with 3.5 mg/mL marimastat solution was initiated immediately 171 
using a Springfusor 30 pump and 30-2 Flow Control Tubing (Allied Medical). 172 
 173 
Sample preparation and analysis 174 
Marimastat concentrations were quantified in plasma, LUF and tissue homogenates 175 
using UPLC-MS on a Nexera UPLC coupled with a MS-8030 Triple quadruple mass 176 
spectrometer (Shimadzu) operating in positive electrospray ionization mode. All reagents 177 
were LC-MS grade. A reverse phase C18 column (Kinetex, 1.7 µm XB-C18, 100A, 50  2.1 178 
mm, Phenomenex) was employed; the injection volume was 1 µL. The mobile phase 179 
consisted of water (Solvent A) and acetonitrile (Solvent B) in the following program: a 180 
gradient run of 5% B and 95% B for 3 min, held for 1 min and then run at 5% B in an 181 
isocratic mode for 2 min. The flow rate was maintained at 0.4 mL/min at a temperature of 50 182 
°C. The drying gas was at 250 °C, the gas flow at 20 L/min, the nebulising gas flow at 3 183 
L/min, and the heating block was at 400 °C. Argon was used as a collision gas, and the 184 
capillary voltage was 4.5 KV. A positive mode with MRM transmission of 332.20  86.15 185 
was used. The dwell time was 100 ms, and the collision energy was set to -20 eV. The limit 186 
of quantification was 10 ng/mL. 187 
 188 
Plasma and LUF samples were extracted using an acid extraction method. 5-189 
sulfosalicyclic acid dihydrate (0.1 g/mL) was added in a 1:1 v/v ratio to the sample. The 190 
sample was vortexed for 30 s, centrifuged for 10 min at 15,625 g and the supernatant 191 
removed, added in a 1:1 v/v ratio to dimethylsulfoxide containing 500 ng/mL of Batimastat
 
192 
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(Vernalis) as an internal standard, vortexed, centrifuged  (10 min, 15,625 g) and the 193 
supernatant removed for analysis. Tissue samples were homogenised in a 1:2 w/w ratio with 194 
water. 5-sulfosalicyclic acid dihydrate (0.1 g/mL) was added to the homogenate in a 1:1 w/w 195 
ratio. The samples were vortexed for 30 s and centrifuged for 10 min at 15,625 g. The 196 
supernatant was removed, added in a 1:1 v/v ratio to dimethylsulfoxide containing 500 ng/mL 197 
internal standard (Batimastat), vortexed, centrifuged (10 min, 15,625 g) and the supernatant 198 
removed for analysis. Calibration and quality control samples were obtained for each matrix 199 
(ultrafiltrate, plasma and tissue homogenate) by spiking the blank matrix with known 200 
amounts of marimastat. The calibration curves were analysed using linear regression with a 201 
minimum R
2
 of 0.99. A measure of in vivo recovery of marimastat in LUF compared to tissue 202 
was calculated using the following equation:  203 
 204 
                 
                       
                   
         205 
 206 
Biochemical analyte concentrations were measured in LUF collected prior to IOIDP 207 
(0-12 h after probe implantation), between IOIDP and CRI (24-36 h post implantation) and 208 
during the last 6 h of the CRI (42-48 h post implantation), using a Beckman Coulter AU400 209 
biochemistry analyser as previously described (Underwood et al., 2014).  210 
 211 
Histological analysis 212 
A lamellar tissue sample surrounding the ultrafiltration probe was fixed in 10% 213 
neutral buffered formalin, processed by routine paraffin embedding, sectioned at 4 µm and 214 
stained with H&E and Masson’s Trichrome for light microscopy as previously described 215 
(Pollitt, 1996). The sections were interpreted by a blinded, specialist veterinary pathologist 216 
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(REA). The reaction around the ultrafiltration probe was scored using a previously described 217 
semi-quantitative method presented in Table 1 (Underwood et al., 2014).  218 
 219 
Data analysis 220 
The relationship between marimastat concentration and pharmacodynamic effect 221 
(MMP degradation of gelatin, expressed as % of control) was estimated using  PKSolver, 222 
employing an inhibitory sigmoid Emax model in which no baseline (E0) was applied as 223 
previously described (Shu et al., 2011). The maximum effect (Emax), the concentration 224 
required for 50% inhibition in vitro (IC50) and the shaping factor (γ) were calculated for pro-225 
MMP2, pro-MMP-9 and active MMP-2. IC80 and IC90 values were estimated for each 226 
protease. Three pharmacokinetic-pharmacodynamic indices were calculated, namely, steady 227 
state concentration (Css):IC50, Css:IC80 and Css:IC90. 228 
 229 
Data were analysed using GraphPad Prism 6.0. The data were tested for normality 230 
using D’Agostino-Pearson omnibus normality tests. Data distributions were either non-231 
Gaussian, or data numbers were too small to presume a normal distribution, hence non-232 
parametric tests were used. Paired data were compared by Wilcoxon signed-rank tests, and 233 
non-paired data by Mann-Whitney tests. Comparisons of repeated measures were analysed 234 
using Friedman analyses with Dunn’s post-tests. Significance was set at P≤0.05. Unless 235 
otherwise stated, data are expressed as median (interquartile range). 236 
 237 
Spearman’s rank correlation coefficients (rs) were calculated to examine the 238 
association between steady-state LUF[M] post IOIDP/CRI with LUF biochemical analyte 239 
concentrations and total histological scores. Data were also examined visually. A weak 240 
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correlation was defined as being significant (P<0.05) with an rs <0.4, moderate 0.4–0.7, and 241 
strong >0.7 (Taylor, 1990). 242 
 243 
Results 244 
There was no difference between IOIDP and CRI infusion rates (0.15[0.14- 0.16] 245 
mL/min vs. 0.15[0.14-0.16] mL/min respectively). This equated to a marimastat infusion rate 246 
of 31.5 mg/h. Both infusions were well tolerated with no evidence of pain or lameness. There 247 
was no change in clinical parameters during either infusion. 248 
 249 
  The in vitro recovery of marimastat through the ultrafiltration probe was 98(95-100)% 250 
in 0.9% saline and 94(90-99)% in plasma. Ultrafiltration probes were placed in the lamellar 251 
tissue in both forefeet in all five horses. LUF was collected at 49(40-55) µL/h. There was no 252 
difference in LUF collection rates during IOIDP (52[39-65] µL/h) and CRI (47[40-54] µL/h), 253 
nor between the IOIDP instrumented foot (50[39-58] µL/h) and the uninstrumented foot 254 
(49[40-58] µL/h). The concentrations of biochemical analytes in LUF did not vary 255 
significantly during the study period (Table 2). Once steady state was reached, there was no 256 
significant difference in LUF[M] during IOIDP or CRI (Fig. 2A). T[M] 12 h into the CRI were 257 
significantly higher than LUF[M] obtained 9-12 h into the CRI (161[136-276] ng/g vs. 258 
145[118-171] ng/g, respectively), resulting in an in vivo recovery of marimastat from tissue 259 
of 72(60-100)%. The within-limb coefficient of variation of marimastat concentrations was 260 
5.9-32.9% in tissue samples and 1.5-6.7% in LUF. 261 
 262 
LUF[M] and P[M] reached steady-state 2 h after initiation of IOIDP and CRI. There 263 
were no significant differences between LUF[M] or P[M] during IOIDP and CRI, nor between 264 
LUF[M] and P[M] after either IOIDP or CRI (Table 4, Fig. 2). There were no differences 265 
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between LUF[M] in the instrumented vs. the un-instrumented limbs during IOIDP or CRI. 266 
However, the LUF[M] in the instrumented limbs during IOIDP were highly variable and 267 
appeared to fall into two groups; two horses (horses 2 and 4, high LUF group) had higher 268 
steady-state LUF[M] (512[469-866] ng/mL) and the remainder (low LUF group) had lower 269 
steady-state LUF[M] (108[65-131] ng/mL, Fig. 3). Neither the P[M] after IOIDP nor the LUF[M] 270 
after CRI differed subjectively between these groups (but numbers were insufficient for 271 
statistical analysis). 272 
 273 
Fig. 4 shows the in vitro inhibition of pro-MMP-2, pro-MMP-9 and active-MMP-2 by 274 
marimastat. PK-PD data are detailed in Tables 3 and 4. Histological examination of the tissue 275 
sections showed the probe situated between primary epidermal lamellae (PEL) in 7/10 limbs 276 
and within the sublamellar dermis in the remaining three horses. There was no significant 277 
difference in steady-state LUF[M] during CRI between probes located in the sub-lamellar 278 
dermis and those located between PEL. The histological changes around the probe were 279 
consistent with a mild foreign body response (Fig. 5). There was no significant correlation 280 
between total histological score and steady-state LUF[M] after IOIDP or CRI. 281 
 282 
Discussion 283 
IOIDP did not consistently result in higher lamellar marimastat concentrations than 284 
IV CRI, nor were the marimastat concentrations in the treated foot consistently higher than 285 
those in the untreated foot and plasma.  Hence IOIDP was not considered a reliable method 286 
for local lamellar drug delivery and the hypotheses were rejected. These results are similar to 287 
those achieved when delivering insulin by IOIDP (de Laat, 2011), and with reports of IO 288 
infusion at sites other than the distal phalanx, where local delivery is generally not achieved 289 
unless a tourniquet is applied (Mattson et al., 2005; Errico et al., 2008) and IO infusion is 290 
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used as an alternative to systemic IV administration (Schalk et al., 2011). However, they 291 
differ from two previous investigations of IOIDP in horses where local lamellar delivery was 292 
successfully achieved (Nourian et al., 2010; de Laat et al., 2012).  293 
 294 
The lack of local lamellar delivery in the present study may be attributable to 295 
variations in IO cannula placement technique (Nourian et al., 2010; de Laat et al., 2012) 296 
possibly causing the infusion to directly enter the systemic circulation. However, insulin 297 
delivery by IOIDP failed to achieve hyperinsulinaemia in veins of the treated foot (de Laat, 298 
2011), despite using a previously successful placement method (Nourian et al., 2010; de Laat 299 
et al., 2012). Therefore further investigations are warranted to determine whether there is a 300 
specific placement site in the distal phalanx that results in local lamellar rather than systemic 301 
delivery. Biodistribution factors attributable to different physicochemical properties of the 302 
pharmaceuticals used may also be responsible for the variation in lamellar delivery during 303 
IOIDP (Bidgood and Papich, 2003). 304 
 305 
Within this study the extent of lamellar delivery by IOIDP varied.  In two horses local 306 
lamellar delivery with IOIDP appeared successful; in the remaining three horses there was no 307 
local delivery effect (Fig. 4). This may be attributable to several factors including variations 308 
in drug metabolism, IOIDP cannula placement, marimastat recovery and probe functionality. 309 
Probe factors were considered unlikely for the following reasons: (1) there was minimal 310 
difference between the in vivo recovery in the high LUF group (85[72-99]%) compared to the 311 
low LUF group (81[57-108]%); (2) the variations in in vivo marimastat recovery (56-108%) 312 
were insufficient to explain the inter-horse variability during IOIDP; (3) the LUF[M]  during 313 
CRI and the LUF concentrations of biochemical analytes did not vary between groups, nor 314 
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did there appear to be any correlation between biochemical analyte and marimastat 315 
concentrations.  316 
 317 
Therefore, the inter-horse variations in LUF[M] during IOIDP probably reflect true 318 
interstitial fluid marimastat concentration variations attributable either to inter-horse 319 
variations in marimastat pharmacokinetics or variations in IOIDP cannula placement, which, 320 
whilst undetectable to the authors, may have resulted in different degrees of lamellar 321 
marimastat delivery. Further investigations, are required to determine whether this variation 322 
occurs to the same extent in a larger population, and to establish its cause. 323 
 324 
Activation of MMP-2, MMP-9, MMP-14, and ADAMTS-4 has been implicated in 325 
inflammatory laminitis pathophysiology (Pollitt et al., 1998; Visser, 2009; Wang et al., 2012). 326 
Zymography established basic pharmacodynamic data for marimastat against equine lamellar 327 
MMP-2 and -9. Marimastat inhibits human MMP-14 and ADAMTS-4 with IC50 values of 0.5 328 
ng/mL and 26.1 ng/mL, respectively (Peterson, 2006; Tortorella et al., 2009). Both CRI and 329 
IOIDP yielded LUF[M] greater than the IC50 of MMP-2, MMP-9, MMP-14 and ADAMTS-4. 330 
Direct extrapolations from IC50 data should, however, be interpreted with caution: frequently 331 
concentrations much higher than the IC50 are required for adequate inhibition in vivo (Lees et 332 
al., 2004; Peterson, 2006).  333 
 334 
Marimastat concentrations required to inhibit lamellar MMPs in vivo are unknown. A 335 
high level of enzymatic inhibition is generally required to produce clinical responses by 336 
MMP-inhibitors, therefore, when available, IC90 concentrations were selected to represent a 337 
therapeutic level of MMP inhibition (Lees et al., 2004; Shu et al., 2011).  There are no 338 
published IC90 values for MMP-14 and ADAMTS-4. Target trough plasma concentrations six 339 
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times the IC50 were employed when the anti-neoplastic activity of marimastat was evaluated 340 
(Millar et al., 1998). Based on this, target concentrations of at least 3 ng/mL and 156 ng/mL 341 
marimastat were set for inhibition of MMP-14 and ADAMTS-4, respectively (Peterson, 342 
2006; Tortorella et al., 2009). IOIDP and CRI yielded steady-state LUF[M] greater than the 343 
target concentrations for MMP-2 and MMP-14 in all horses. However, neither technique 344 
consistently achieved target LUF[M] for MMP-9 and ADAMTS-4. Therefore it is questionable 345 
whether, at the rates used in this study, either technique would sufficiently inhibit lamellar 346 
MMPs in vivo. 347 
 348 
IOIDP was performed without complication in all five horses. IOIDP in horses has 349 
previously been associated with signs of pain (pawing and weight shifting) (de Laat, 2011). 350 
Pain associated with IO infusion is also reported in people and lidocaine administration is 351 
recommended to counteract this (Schalk et al., 2011). The horses in our study received 352 
lidocaine to block pain associated with IOIDP. As co-administration with lidocaine may have 353 
altered the pharmacokinetics of marimastat, lidocaine was also infused during CRI. The 354 
results of this study indicate IOIDP with lidocaine did not result in noticeable foot pain when 355 
the horses were free to move in the stall; further lameness evaluation would be necessary to 356 
declare the technique ‘pain free’. 357 
 358 
This is the first study to describe the use of ultrafiltration to collect LUF for 359 
pharmacokinetic analyses and compare simultaneous tissue and ultrafiltrate concentrations. 360 
An additional objective was to validate lamellar ultrafiltration for pharmacokinetic studies. 361 
LUF was successfully collected from every probe placed. Probes were well tolerated and 362 
functioned for the duration of the study. LUF collection rate did not vary significantly with 363 
time, and was sufficient for analysis. Based on comparison of T[M] and LUF[M] at the end of 364 
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the CRI, in vivo marimastat recovery was 72%. A <100% in vivo recovery rate is expected as 365 
‘in vivo recovery’ is a comparison between unbound drug concentrations in LUF and total 366 
drug concentrations in tissue, not a direct measure of probe function (Bidgood and Papich, 367 
2003). The in vitro variability in marimastat recovery was minimal (range 90-102%); 368 
whereas inter-horse variability in ‘in vivo recovery’ (LUF vs. tissue marimastat 369 
concentration) was high (range 56-108 %). This was attributed to the high within-limb 370 
variation in T[M], ascribed to inaccuracies during the complicated homogenisation and 371 
extraction process, and reflects a limitation of using tissue homogenates in pharmacokinetic 372 
studies.  373 
 374 
Key concerns with ultrafiltration include whether drug recovery remains constant over 375 
time or is affected by tissue response to the ultrafiltration probes. The histological findings in 376 
this study support those in a previous report, with mild inflammation and fibrous tissue 377 
formation around the probes (Underwood et al., 2014). These changes may alter drug 378 
recovery (Wisniewski et al., 2001). In the present study, there were no significant differences 379 
in LUF[M] during steady state, suggesting marimastat recovery was consistent. The lack of 380 
significant temporal variations in LUF biochemical analyte concentrations and any 381 
correlation between biochemical analyte concentrations or steady-state LUF[M] and total 382 
histological score suggests host tissue response had minimal effect on recovery.  383 
 384 
A major limitation of this study was the small number of horses used. Initially, power 385 
calculations were performed to ensure sample size was sufficient whilst minimising the 386 
number of horses used in accordance with the welfare principles governing animal research 387 
(NHMRC, 2013). However, the high variability in LUF[M]  after IOIDP was not anticipated. 388 
During IOIDP, the infusion rate varied very slightly in each horse (range 0.13- 0.17 mL/min), 389 
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presumably due to inter-horse variations in resistance to infusion. However, CRI was 390 
performed after IOIDP to ensure CRI infusion rates were matched to the IOIDP rate in each 391 
horse.  392 
 393 
Conclusions 394 
Both IOIDP and CRI of marimastat at a rate of 31.5 mg/h yielded sufficient LUF[M]  to 395 
inhibit 50% of MMP-2, MMP-9, MMP-14 and ADAMTS-4 in vitro, and hence may have 396 
potential for laminitis prophylaxis. However, neither technique resulted in consistent local 397 
lamellar delivery at concentrations considered sufficient for effective in vivo inhibition of 398 
MMP-9 and ADAMTS-4. Based on the results of this study, CRI is more suitable for lamellar 399 
marimastat delivery as it is simpler, yields similar median lamellar marimastat concentrations 400 
and has potential to deliver high volumes of pharmaceutical. The CRI dose requires 401 
optimisation to ensure target lamellar marimastat concentrations are achieved prior to 402 
application in experimental studies evaluating the efficacy of marimastat as a laminitis 403 
prophylactic. However, CRI is a systemic delivery technique and even its experimental use 404 
may be precluded by cost so further investigation of alternative local delivery mechanisms, 405 
such as retrograde IV infusion of the distal limb under tourniquet, is warranted. If IOIDP 406 
could be optimised to consistently yield the higher rate of lamellar delivery achieved in 2/5 407 
horses in this study it may be worthy of further development.  Lamellar ultrafiltration played 408 
a key role in supplying samples of LUF for pharmacokinetic analysis. The successful use of 409 
lamellar ultrafiltration in this study demonstrated its potential for use in further 410 
pharmacokinetic studies investigating lamellar drug delivery.    411 
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Figure Legends 506 
Fig. 1:  The custom made intraosseous infusion needle and 25 mm long flushing needle used 507 
to remove debris from the holes drilled in hoof and bone.  508 
 509 
Fig. 2: Median (±IQR) marimastat concentrations during intraosseous infusion of the distal 510 
phalanx (IOIDP) and systemic continuous rate infusion (CRI) with marimastat. (A) Lamellar 511 
ultrafiltrate marimastat concentrations (LUF[M]) during IOIDP (black circles) and CRI (grey 512 
squares). (B) Plasma marimastat concentrations (P[M]) during IOIDP (black circles) and CRI 513 
(grey squares). (C) P[M] (grey triangles) and LUF[M] (black circles) during IOIDP.  (D) P[M] 514 
(black triangles) and LUF[M] (grey squares) during CRI. There were no significant differences 515 
between any of the concentrations at any time-points. 516 
 517 
Fig. 3: Box and whisker plot showing steady-state ultrafiltrate marimastat concentrations in 518 
each horse during IOIDP.  519 
Fig. 4: (A) Zymography of a lamellar homogenate pooled from horses with oligofructose-520 
induced laminitis. MMP inhibition was achieved by incubating individual gel lanes with 521 
increasing concentrations of marimastat. (B) % inhibition of lamellar MMP gelatin 522 
degradation by increasing concentrations of marimastat.   523 
Fig. 5: Median (±IQR) histological scores of lamellar sections surrounding the ultrafiltration 524 
probe. 525 
 526 
Table 1: The semi-quantitative histological scoring system applied to the lamellar slides. 527 
Score 0 1 2 3 
 
Epidermal basal cell and parabasal cell 
hyperplasia: expressed as fold increase in 
Normal  2 fold  3 fold ≥ 3 fold  
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thickness of epidermal cell layer 
 
Flattening of secondary epidermal lamellae 
(SEL): expressed as % of length of unaffected SEL 
remaining 
 
100% 66-99% 50-66% <50% 
Mitotic figures: per high power field at 200x 
magnification in the most affected area 
 
0 1  2 ≥3 
Inflammatory cell count surrounding the probe 
 
0 1-50 50-100 >100 
Fibroplasia: thickness of the fibrous tissue around 
the probe compared to the width of  unaffected 
primary epidermal lamellae (PEL) 
 






Collagen bundle formation Absent Mild  Moderate Marked  
 
Cellular debris  Absent Mild  Moderate Marked  
 
Endothelial reactivity: the number of vessels with 
reactive endothelium around the probe 
 
0 1-20 21-50 >50 
Lamellar necrosis: the number of necrotic PEL 0 1 2 3  
 528 
  529 
Page 21 of 25
22 
 
Table 2: The results of the biochemical analyses of ultrafiltrate through the study, data are 530 
reported as median (IQR). There were no significant differences in analyte concentrations at 531 
any of the time points. 532 
Analyte 0-12 h post 
probe placement 
24-36 h post 
probe placement 
42-48 h post 
probe placement 
Urea (mmol/L) 7.0 (5.7-8.6) 6.1 (5.0-7.6) 5.6 (5.4-6.4) 
Glucose (mmol/L) 2.9 (0.7-4.2) 3.2 (0.7-3.9) 2.7 (0.0-3.2) 
Sodium (mmol/L) 137 (134-140) 131(129-134) 136 (133-138) 
Potassium (mmol/L) 4.2 (4.0-4.4) 3.9 (3.9-4.3) 4.2 (4.1-4.4) 
Chloride (mmol/L) 106 (104-110) 103 (102-104) 107 (104-108) 
 533 
  534 
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Table 3: Estimates of pharmacodynamic parameters for marimastat inhibition of equine 535 
lamellar matrix metalloproteinases (MMPs) MMP-2 and MMP-9 in vitro. 536 
 Pro-MMP-9 Pro-MMP-2 Active-MMP-2 
Emax (%) 102.8 (97.2-106.6) 114(105-119) 105(103-109) 
γ 0.75(0.65-1.13) 0.64(0.62-0.92) 0.9(0.7-1.3) 
IC50 (ng/mL) 9.2(7.4-18.8) 2.8(1.6-3.5) 2.5(2.0-3.6) 
IC80 (ng/mL) 66(54-79) 25(16-38) 20(20-20) 
IC90 (ng/mL) 177(131-260) 81(38-116) 40(18-56) 
 537 
Emax, maximum effect; IC50, concentration required for 50% inhibition in vitro; γ, shaping 538 
factor.  539 
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Table 4: Estimates of pharmacokinetic-pharmacodynamic parameters for MMP-2 and MMP-540 
9 after marimastat administration by intraosseous infusion of the distal phalanx (IOIDP) and 541 
systemic constant rate infusion (CRI). Data expressed as median (IQR) 542 
 IOIDP LUF IOIDP plasma CRI LUF CRI plasma 
Css (ng/mL) 139(88-497) 103(69-114) 136(93-157) 105(85-156) 
Css:IC50-MMP9 15(9.0-55) 14(9.0-14) 11(9.1-18) 11(2.1-7.7) 
Css:IC90-MMP9 0.8(0.5-2.9) 0.7(0.5-1.0) 0.6(0.5-0.7) 0.6(0.5-0.9) 
Css:IC50-MMP2 50(29-181) 47(30-63) 37(30-45) 37(30-59) 
Css:IC90-MMP2 1.7(1.0-6.3) 1.6(1.0-2.2) 1.3(1.0-1.6) 1.3(1.0-2.0) 
Css:IC50-MMP2_active 56(33-203) 53(33-71) 41(33-51) 41(34-66) 
Css:IC90-MMP2_active 3.5(2.1-12.7) 3.3(2.1-4.4) 2.6(2.1-3.2) 2.5(2.1-4.1) 
 543 
LUF, lamellar ultrafiltrate, Css, steady-state concentration (ng/mL). 544 
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